Drug Profile
Bevacizumab biosimilar - Biocon/Viatris
Alternative Names: Abevmy; KRABEVA; Lextemy; MYL 1402OLatest Information Update: 24 Feb 2024
Price :
$50
*
At a glance
- Originator Biocon
- Developer Biocon; Viatris Inc
- Class Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Brain cancer; Breast cancer; Cancer; Cervical cancer; Colorectal cancer; Fallopian tube cancer; Glioblastoma; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Renal cancer; Renal cell carcinoma
Most Recent Events
- 08 Feb 2024 Launched for Cancer in Australia (IV)
- 08 Feb 2024 Biocon Biologics enters into distribution agreement with Sandoz to distribute Trastuzumab biosimilar in Australia
- 03 Aug 2023 Launched for Breast cancer (Combination therapy, First-line therapy, Metastatic disease) in Poland (IV) (Biocon website, August 2023)